Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Fierce Pharma
Daiichi Sankyo targets global top 5 oncology rank by 2035
By 2030, Daiichi envisions its revenues will reach more than 3 trillion yen ($19.1 billion), with 2.3 trillion yen from its oncology portfolio.
Angus Liu
May 11, 2026 10:22am
Daiichi pens pact for high cholesterol digital therapeutic
Mar 5, 2026 9:20am
BioNTech’s B7-H3 ADC hits ph. 3 at half the size of Merck’s
Feb 27, 2026 10:31pm
Sarepta CEO to step down as DM1 hits home—Chutes & Ladders
Feb 27, 2026 8:30am
Daiichi picks former Novartis CMO John Tsai to head up R&D
Feb 20, 2026 4:56am
Daiichi stops internal development of next-wave ADC
Feb 2, 2026 10:55am
